Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Exact Science’s Revenue Breakdown Worldwide from Q1 2016 onwards, split between the United States, and Outside of the US (Rest of the World), reported on a quarterly basis.
With a main portfolio of merchandise for earlier cancer detection and remedy steering, the company offers smarter solutions to sufferers in advance. Their contemporary services and products include screening exams and precision oncology exams. Exact Science’s studies and improvement efforts are targeted on development of new merchandise and improving present merchandise to cope with new cancer in different regions. They aim to increase the medical software and address the affected population.
They are focused on improving their Cologuard test. These improvement efforts can also additionally result in lots of new feasible merchandise, such as chance assessment, screening and prevention, early ailment diagnosis, adjuvant and/or neo-adjuvant ailment remedy, metastatic ailment remedy selection, and affected person monitoring.
|Revenue by Region||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
|Outside of US||$16.24||$26.85||$27.23||6.0%|
(All figures are in millions, except percentages)
The total revenue of 2021 has shown an increase of $48.02 million, from $408.36 million in Q3 2020 to $456.38 million in Q3 2021, making an increment of about 11.75% on a year-on-year basis. It increased by 4.95% on a quarter-on-quarter basis, as compared to $434.82 million in Q2 2021. Moreover, for the latest quarter Q3 2021, 94% of the revenue can be traced back to the United States, whereas all other countries contribute 6% of the revenue.
The healthcare enterprise in the United States has skilled a fashion towards value containment and value-based shopping of healthcare offerings. Some authorities and personal payers are adopting pay-for-overall performance packages that differentiate bills for healthcare offerings, primarily based on the fulfilment of documented pleasant metrics, value efficiencies, or affected person outcomes. Payers can also additionally appear to pleasant measures together with the NCQA, HEDIS, and the CMS Medicare Advantage Star Ratings to evaluate the quality of care.
The revenue from the United States has a major contribution of 94% to the total revenue of the company. From $392.12 million in Q3 2020 to $429.15 million in Q3 2021, the company’s revenue rose by 9.43% on a year-on-year basis. It also grew by $21.18 million on a quarterly basis, making an increment of 5.19%, as compared to $407.97 million in Q2 2021.
Outside of US
The company is now commercializing its Oncotype IQ exams across the world via personnel in Canada, Japan, and 6 European nations, in addition to specific distribution agreements. They have introduced their Oncotype IQ exams in greater than ninety nations outside of the US.
Revenue from other countries contributed 6% to the total revenue of the company. The company’s Revenue has shown an increase of $10.99 million, from $16.24 million in Q3 2020 to $27.23 million in Q3 2021, making an increment of 67.67% on a year-on-year basis. Revenue has also shown an increase of 1.41% on a quarterly basis, as compared to $26.85 million in Q2 2021.
The company is founded on 1 January 1995, in Marlborough, Massachusetts. It is headquartered in Madison, Wisconsin, US. Found by Stanley Lapidus and Anthony P. Shuber, Exact Sciences Corporation is a molecular diagnostics company specializing in the early detection cancers. It is a worldwide cancer screening and diagnostics company. They have evolved a number of the impactful manufacturers in cancer diagnostics, and are presently aiming towards improving their examinations, providing new, modern cancer exams to sufferers all through the world.
They are devoted to supplying advance solutions and remedy steering to assist humans in facing the maximum hard selections with confidence. From early cancer detection to remedy steering, they are seeking to assist humans to get the solutions they want to make greater, knowledgeable selections throughout the cancer continuum. Their sales are generated through their laboratory trying out offerings, from Cologuard colorectal cancers screening to Oncotype IQ cancers diagnostic exams and offerings, and COVID-19 test. The common stock of the company is publicly traded on the NASDAQ under the symbol “EXAS” and is a component of the Russell 1000 index.
Did you like Exact Sciences’ Revenue Breakdown Worldwide statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.